SUMMARY The presence of type IV hypersensitivity to cardiac antigens in 26 patients with congestive cardiomyopathy was sought by two in vitro techniques. Neither test showed a significant group abnormality, but 10 patients did have hypersensitivity to heart antigen, in particular to congestive cardiomyopathic heart antigen. These patients were characterised by worse haemodynamic data and a more rapid and malignant course of the disease than in the rest of the group.
Immunological abnormalities are known to occur in congestive cardiomyopathy, but their role and importance in aetiology have not been determined.' 2 The possibility that an insult to the heart such as a viral infection might initiate damage which immunological mechanisms then perpetuate has been suggested.34 Raised virus titres have been reported in congestive cardiomyopathy without the isolation of virus particles in the myocardium. 45 Animal experiments have shown that acute viral infections of the heart can progress to chronic myocardial damage where evidence of virus is absent after the first few days of infection6; T cell function appears to be important in determining the long term outcome of these infections.78 A viral antigen or an abnormal cardiac antigen exposed by a virus may be responsible for setting up a hypersensitivity reaction which would continue after the infection had disappeared. Type IV hypersensitivity to heart antigens has been reported in a proportion of patients with congestive cardiomyopathy,9 10 but whether the abnormality is primary or secondary, or whether those with such apparent autoimmunity comprise only a subset of patients with congestive cardiomyopathy, or whether the tests used to detect hypersensitivity are not sensitive enough is not known.
This study examined the possibility that type IV hypersensitivity to cardiac antigens is an underlying mechanism of damage in congestive cardiomyopathy.
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Patients and methods a
Twenty six patients with congestive cardiomyopathy diagnosed according to the classification of Goodwin and Oakley" I were studied. All but two patients had undergone cardiac catheterisation, which showed normal coronary arteries and histological compatibility with the diagnosis on endomyocardial biopsy' 2; in the two exceptions, the diagnosis was confirmed at necropsy. For comparison, a group of 26 patients with ischaemic heart disease matched for symptoms using the New York Heart Association classification were studied (Table 1) ; mean haemodynamic data are also shown in Table 1 for the two patient groups, and there were no significant differences between them (Student's unpaired t test). A third group of 18 normal healthy controls were age and sex matched with the cardiomyopathy group.
Type IV hypersensitivity is a cell mediated (or delayed) type of hypersensitivity usually involving T lymphocytes and non-specific inflammatory cells. It was studied by two in vitro techniques: leucocyte migration inhibition and lymphocyte transformation using cardiac muscle preparations as the antigens. Details of the methods are previously described by Lowry et al,'3 and the procedures in this study were identical except for the use of different antigens. Fisher exact probability test where numbers were small) was used as a test of significance when inhibited and non-inhibited groups were compared.'5 The Mantel-Haenszel test was used to test the significance of differences between the groups for survival. 16 
Results
The leucocyte migration inhibition test did not show significant differences between the three groups when tested with normal heart antigen (0-99>p>098), congestive cardiomyopathic (A) antigen (0*90> p>0-80), congestive cardiomyopathic (B) antigen (0-30>p>0-20), or hypertrophic cardiomyopathic antigen (050>p>0O30). A migration inhibition index <0X80 is usually considered to represent inhibition. 1 7 Table 2 shows the percentage of patients showing such inhibition for each group and each antigen. Although more of the congestive cardiomyopathic group were inhibited by the normal and congestive cardiomyopathic (A) and (B) heart antigens, none of these differences reached statistical significance.
Not all the patients were tested successfully with all antigens as some died or had operations before testing was complete. The patients were initially tested with normal and congestive cardiomyopathic (A) hearts so the number of results are greater with these antigens. Using these antigens, 10 of 25 congestive cardiomyopathic patients, four of 22 ischaemic heart disease patients, and two of 18 normal controls were (Table  3 ). The mean duration of illness in these seven patients was 27 months compared with 48 months for the remainder of the group. Five of the seven died before the end of the study. The duration of illness for these five was 19 months, and all had been tested with congestive cardiomyopathic (A) antigen within three months of death.
One of the two normal controls who showed inhibition with normal heart antigen was the identical twin brother of one of the congestive cardiomyopathic patients who showed inhibition with both normal heart and congestive cardiomyopathic (A) antigens and who died. One normal control was inhibited with both normal and congestive cardiomyopathic (A) heart antigens. None of the ischaemic heart disease patients were inhibited with more than one antigen.
Testing with congestive cardiomyopathic (B) antigen did inhibit some different patients in the cardiomyopathic group, but there was some overlap with those already showing inhibition with other heart antigens. Finally, testing with hypertrophic cardiomyopathic antigen did not show inhibition predominantly in any one group, and there was overlap with patients showing inhibition with other antigens. Figure 3 shows the lymphocyte transformation results; two different concentrations of normal heart antigen and congestive cardiomyopathic (A) antigen are represented. The variation in results was wide, but no stimulation occurred with either antigen, and there were no significant differences between the groups. In view of these results, lymphocyte transformation was not attempted with congestive cardiomyopathic (B) or hypertrophic cardiomyopathic antigens. successfully used as tests of celluIn this study, neither leucocyte migration inhibito various antigens. 18 Inhibition tion nor lymphocyte transformation to heart antigens )hokines in the presence of tissue showed significant differences between the groups. resensitisation of the cells, a There did, however, appear to be a group of patients ue that would not be expected in in the cardiomyopathic group who did show leucocyte Nevertheless, no test of cellular migration inhibition (migration index <0 80) when hat T cells are primarily respons-compared with the other groups using a normal heart ,,e. 19 and congestive cardiomyopathic antigens; the numion inhibition has been widely bers did not reach statistical significance but the ersensitivity and shown to corre-finding did raise some interesting points. One of the d type skin testing,20 for exam-difficulties of this study was that by the very nature of itive and negative individuals.2' the illnesses, patients in the ischaemic and carin test was available, whereas in diomyopathic groups died before all testing was comitigens in which skin testing was plete. few patients with ischaemic heart disease who showed 404 inhibition with normal heart or congestive cardiomyopathic (A) antigens were not necessarily those with poor left ventricular function (Table 3) suggesting that such sensitisation is not merely the result of end stage cardiac damage whatever the cause.
These results are similar to those of other groups who have also found small numbers of patients within the cardiomyopathy group showing hypersensitivity to heart antigens.'024 There are several possible explanations for these findings. Differing aetiologies may lead to different antigens being exposed; for example, a virus might predispose to the exposure of a particular antigen so that only those patients sensitised to that particular antigen would show hypersensitivity. It is interesting that the congestive cardiomyopathic (A) heart antigen was from a boy who had a rapidly progressive illness, as had those showing inhibition with his heart. Different congestive cardiomyopathy antigens did not, however, identify separate and distinct groups of patients, but overlap was seen. The nature of the antigens in such preparations of heart muscle was very important. They undoubtedly consist of a mixture of soluble cytoplasmic and membrane proteins. Sterility was achieved by ultrafiltration, and this excluded the bulk of possible antigenic material especially membrane bound antigens. The use of a soluble antigen preparation in any case is less likely to cause inhibition than a particulate antigen. 17 It is possible that the major part of the antigen of prime importance is lost altogether in the preparation. It may be that hypersensitivity occurs terminally, and this would explain why inhibition was often present within three months of death. Also the response to the heart preparation did not seem to be specific to the cardiomyopathy group or indeed to patients with heart disease since even the normal group had individuals showing a positive response. It was of interest that the twin brothers both showed inhibition with normal heart antigens; perhaps it is these people who, with the appropriate stimulus, will procede to develop congestive cardiomyopathy.
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